Toward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment
The leishmaniases are a group of diseases caused by protozoan parasites—Leishmania sp. Leishmaniasis is classified among the 20 neglected diseases by WHO. Although the disease has been known for more than 120 years, the number of drugs used for the treatment is still limited to 5–6. The first-line d...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/79559 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Toward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment
- Quinazoline and Its Derivatives: Privileged Heterocyclic Scaffolds in Antileishmanial Drug Discovery
- Visceral leishmaniasis: Therapeutic challenges and the potential of microalgae as a source of antileishmanial compounds
- Leishmaniasis: Possible New Strategies for Treatment
- Treatment of Leishmaniasis
- Fused Pyridine Derivatives: Synthesis and Biological Activities
- New Molecular Targets and Treatments for Pediatric Brain Tumors